Eltair

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eltair

Property Description
Active ingredient Budesonide
Form Aqueous Suspension (e.g., Nasal Spray)
Pharmacological class Corticosteroid (Glucocorticoid)
Origin Synthetic (Non-halogenated steroid)
General Purpose Prophylactic control of chronic inflammation

What Type of Medicine is Eltair?

Eltair is a medication whose active component is Budesonide, a synthetic drug that belongs to the corticosteroid class. Specifically, Budesonide is known pharmacologically as a potent glucocorticoid, meaning its primary function is to reduce inflammation. This compound is a synthesized, non-naturally occurring steroid categorized as a non-halogenated cyclic ketal corticosteroid. The drug is designed as a single product, containing only Budesonide as the active therapeutic compound, distinguishing its focus from combination formulas.

Form, Composition, and General Purpose

The specific product known as Eltair is often supplied as an aqueous suspension for intranasal application via a nasal spray device. While the active ingredient, Budesonide, is used in other forms, the Eltair nasal spray is engineered for targeted relief. This targeted delivery strategy is key: Budesonide is designed for high topical potency and low systemic bioavailability. This low systemic exposure means the drug acts strongly at the application site and is rapidly metabolized, limiting the amount that enters the general circulation. Consequently, the medicine is primarily used as a maintenance or prophylactic agent for the sustained control and prevention of chronic swelling and irritation.

Regulatory References

  1. Budesonide - StatPearls - NCBI Bookshelf

What side effects are possible with Eltair?

Possible Side Effects and Safety Information: Eltair

Adverse reactions documented in official regulatory sources are systematically categorized by frequency and the body system affected (System-Organ Class or SOC) to define the medicine's safety profile.

Serious Adverse Reactions

The regulatory labeling includes a prominent Black Box Warning to highlight the potential for Anaphylaxis (severe, life-threatening allergic reactions). These reactions can occur suddenly, even after a patient has received the medicine previously, and may require immediate medical attention. Malignancy (the development of new cancers) has also been observed in clinical studies and is classified as a serious risk that warrants consideration.

Adverse Reactions by Frequency

Adverse effects are documented using standardized frequency classifications (e.g., Very Common, Common, Uncommon) as defined by regulatory bodies. Injection-related reactions (such as pain, swelling, or redness at the administration site) are typically noted as Very Common or Common events.

Other frequently reported adverse reactions are cataloged under specific System-Organ Classes, which may include conditions affecting the nervous system, infections, or general disorders. The official documentation may also describe specific exposure-related patterns, such as certain adverse reactions being more frequent at the start of therapy and decreasing over time.

Safety Restrictions and Limitations

Formal contraindications (situations where the medicine must not be used) are specified, primarily involving known hypersensitivity to the active substance or excipients. Safety documentation outlines population-specific considerations, detailing risks or cautions for use in defined patient groups, such as those with pre-existing medical conditions or specific age ranges. Close monitoring for certain signs is mandated as a safety note in the official labeling to manage risks defined in these categories.

Overdose and Emergency Response

If you suspect an overdose of Eltair, even if symptoms are mild or uncertain, seek emergency medical help immediately. An overdose is a medical emergency that requires immediate professional attention. Never attempt to treat an overdose at home or wait for symptoms to worsen.

Overdose with this class of medication can lead to a range of severe effects due to the central nervous system depressant properties. The severity of symptoms depends on the amount taken, whether it was combined with other substances like alcohol, and the individual's overall health.

Recognizing an Overdose

Signs and symptoms of a serious overdose may include, but are not limited to, the following:

Symptom Category Potential Signs
Consciousness Profound drowsiness, confusion, inability to be awakened (unconsciousness).
Respiration Slowed, shallow, or stopped breathing (respiratory depression).
Circulation Low blood pressure, slow or weak pulse.
Physical Signs Cold, clammy skin; limp muscles.

When to Seek Help

Call your local emergency number (such as 911 or the equivalent local service) or Poison Control right away if any of these events occur or if an overdose is suspected. Be prepared to provide the name of the medication (Eltair), the amount taken, and the time it was ingested. Treatment often involves supportive care, monitoring of vital signs, and potentially specific reversal agents administered by healthcare professionals.

Ensure that the person remains under constant observation until emergency personnel arrive. Even after initial symptoms subside, continued medical evaluation is essential.

Therapeutic Uses of Eltair

What Eltair Treats: Main Uses and Benefits

Eltair (budesonide nasal spray) is commonly used to help with symptoms related to inflammatory or irritative states within the nasal passages. This medication is commonly applied in the therapeutic domain of seasonal or perennial allergic rhinitis in patients 6 years of age and older. It is generally applied in settings where additional symptomatic support is needed for moderate to severe persistent symptoms.

The main clinical uses involve conditions characterized by periods of heightened symptoms, specifically allergic rhinitis (both seasonal and year-round) and addressing symptoms associated with nasal polyps. This medication helps address symptom clusters that include frequent sneezing, nasal itching, and excessive watery nasal discharge, which are common in allergic conditions.

Key Therapeutic Domains

It also targets physical discomfort from chronic nasal congestion and blockage. This therapeutic use assists with maintaining functional stability, contributing to improved day-to-day comfort. For patients with nasal polyps, Eltair is applied in addressing these inflammatory growths. This use is relevant when supportive symptom management is appropriate to reduce the size of the growths and supports clearer nasal airflow.


Quick Fact: Relief for Nasal Congestion The benefit patients may receive is support for easier nasal breathing, which contributes to improved day-to-day comfort and may support improved sleep comfort during symptomatic periods.

Eligibility and Restrictions for Use

The eligibility for Eltair (budesonide nasal spray) is strictly defined by government regulatory documentation based on age, known allergies, and certain pre-existing medical conditions.

Eligibility Scope

Classification Status According to Regulatory Labels
Populations Allowed Adults and children 6 years of age and older for treatment of allergic rhinitis.
Use Not Recommended Children younger than 6 years of age (safety and efficacy not established).
Contraindicated Patients with a known hypersensitivity or allergy to Budesonide or any other component in the formulation.

Condition-Specific Restrictions

Official labels describe conditional or restricted use for specific patient groups, requiring caution or close monitoring:

  • Hepatic Impairment: Patients with severe liver disease should be monitored closely, as the medicine's systemic exposure may increase.
  • Local Nasal Conditions: Use should be avoided in patients with unhealed wounds, recent nasal surgery, or nasal trauma until recovery is complete.
  • Infections: Use requires caution in patients with existing or a history of tuberculosis, untreated fungal, bacterial, or systemic viral infections, or ocular herpes simplex.

Pregnancy and Lactation Status

  • Pregnancy: Use is generally permitted only if the potential benefit justifies the potential risk to the fetus, as documented in regulatory guidelines.
  • Lactation: The active substance is excreted into human milk. The decision for use should be made with caution, considering the importance of the drug to the mother.

What should I know about interactions with other medicines?

Eltair contains both a corticosteroid and a Long-Acting Beta2-Agonist (LABA), which leads to specific drug interaction warnings based on the properties of both components.

Pharmacokinetic Interactions (Metabolism)

Strong CYP3A4 Inhibitors are expected to increase the systemic exposure of the corticosteroid component. Since this component is metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system, co-administration with strong inhibitors, such as ketoconazole, should be approached with caution. This combination may increase the risk of systemic corticosteroid effects.

Pharmacodynamic and Related Interactions

Interacting Product Category Potential Effect Regulatory Caution Level
Other Long-Acting Beta2-Agonists (LABAs) Risk of overdose and serious cardiovascular effects. DO NOT USE
Anticholinergics Potential for additive anticholinergic effects. Avoid
Monoamine Oxidase Inhibitors (MAOIs) & Tricyclic Antidepressants (TCAs) May potentiate the beta-agonist component's effect on the vascular system. Use with Extreme Caution
Non-selective Beta-blockers May block the bronchodilatory effect and induce severe bronchospasm. Use with Caution
Non–potassium-sparing Diuretics May worsen hypokalemia and electrocardiographic (ECG) changes associated with the beta-agonist component. Use with Caution

Due to the inclusion of a LABA, Eltair must not be co-administered with any additional medicine containing a LABA for any reason, as this increases the risk of serious cardiovascular events and potential fatality. Clinically significant interactions with strong CYP3A4 inhibitors, certain antidepressants, and diuretics are primarily related to the metabolic pathways of the corticosteroid and the sympathomimetic effects of the LABA component, requiring close clinical observation if combination therapy is necessary.

Mechanism of Action

Mechanism of Action: Eltair (Budesonide)

Eltair's activity is rooted in its ability to influence the cell's genetic code, leading to sustained modulation of local inflammatory processes.

The active component, Budesonide, functions as an agonist for the intracellular Glucocorticoid Receptor (GR). This binding initiates a genomic effect: the activated drug-receptor complex enters the cell nucleus to perform both transactivation (increasing transcription of anti-inflammatory genes) and transrepression (blocking pro-inflammatory transcription factors like Nuclear Factor kappa B ( NF-kappa B)). This mechanism shifts the cell's output from generating inflammatory signals to suppressing them.

This genetic shift leads to the comprehensive dampening of key inflammatory pathways. The mechanism suppresses the production of potent mediators such as Prostaglandins, Leukotrienes, and pro-inflammatory Cytokines. By reducing these chemical signals, the drug limits the infiltration and activity of immune cells (like eosinophils), which affects tissue fluid leakage and contributes to the maintenance of a stable physiological environment. The action is characterized by a delayed onset because it is dependent on gene transcription and the synthesis of new proteins, making it optimally suited for sustained biological regulation.

Dosage and Administration Information

How to Use Eltair (Ambrisentan)

Standard clinical protocols for this medication specify the route, dosage, schedule, and necessary monitoring procedures. The medicine is available as 5 mg and 10 mg film-coated tablets for oral administration.

Administration and Dosing

Instruction Category Official Requirement (Adult Dosage)
Starting Dose Initiate treatment at 5 mg once daily.
Dose Titration The dose may be increased to 10 mg once daily if the 5 mg dose is tolerated, typically at 4-week intervals or more.
Timing & Preparation Take the tablet once daily, with or without food. Tablets must be swallowed whole; do not split, crush, or chew.
Missed Dose If a dose is missed, continue with the next dose at the usual time. Do not take two doses at the same time.

Procedural and Population Requirements

The full administration protocol involves specific steps beyond tablet consumption. Liver aminotransferase levels are measured prior to initiating the medicine and at least every month thereafter to monitor for potential liver injury. In patients concurrently taking the drug cyclosporine, the dose of ambrisentan is limited to a maximum of 5 mg once daily. Doses higher than 10 mg once daily have not been studied and are not part of the standard regimen. Use in pediatric patients has not been established.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eltair

Evidence for Use in Seasonal and Perennial Allergic Rhinitis

Research exploring the use of Eltair in patients with allergic rhinitis is primarily based on placebo-controlled randomized clinical trials (RCTs). These studies were used in research exploring how symptoms change over time for both seasonal allergies and year-round perennial allergies. The clinical trials were applied in studies examining patient-reported experiences, focusing on outcomes related to physical discomfort in the nasal passages. Researchers monitored outcomes related to symptoms such as sneezing, itching, runny nose, and nasal blockage, often using a composite score to record symptom measurements. Studies reported measurements taken during the study period when comparing those who received the active medicine against those who received an inactive placebo. Evidence derived from settings with varying symptom burdens is included in the research landscape, but some studies reported mixed findings or direct comparison studies with other available treatments are limited.

Evidence for Use in Nasal Polyps

The research base involving patients with nasal polyps, which are conditions characterized by functional limitations and periods of heightened symptoms, was evaluated in randomized controlled trials. These studies primarily focused on adult populations diagnosed with chronic rhinosinusitis and polyps. The research examined outcomes linked to inflammatory or irritative states, including objective measurements of polyp size using specialized Endoscopic Nasal Scores. Studies also monitored patient-reported outcomes describing perceived discomfort and quality of life. Certainty remains low for some aspects of this condition, and follow-up durations were limited in the primary trials, typically extending to only 3 to 6 months. Data are insufficient for long-term outcomes related to polyp recurrence or sustained functional improvement over a year or more.

What is Still Uncertain or Limited in the Research

Research exploring short-term symptom changes typically included follow-up durations that were limited, lasting only a few weeks in many cases. Long-term effects are not fully established for continuous, year-round use over extended periods. For instance, limited information is available regarding outcomes for older adult populations (age 65 and older) or for pregnant or breastfeeding individuals, as these groups were typically excluded from the primary efficacy trials. Comparative evidence is lacking in some areas, and sample sizes were modest in some of the specialized trials, meaning the research describes group patterns, not individual predictions.

Key Studies & References

  1. Comparative efficacy and acceptability of licensed dose intranasal corticosteroids for moderate-to-severe allergic rhinitis: a systematic review and network meta-analysis
  2. Efficacy of Budesonide Nasal Administration in the Management of Chronic Rhinosinusitis: Meta-Analysis of Randomized Clinical Trials (Focus on Polyps and Delivery Methods)
  3. Comparison of Corticosteroids Effectiveness via High Volume Nasal Irrigation versus Conventional Nasal Spray after Endoscopic Si (Study discussing limitations of conventional spray for polyps)

Frequently Asked Questions (FAQ)

Common questions about Eltair (FAQ)


Q: How quickly should I expect to see an effect from Eltair?

Official patient information indicates that some individuals may notice a change in symptoms on the very first day of use. However, for maximum relief and the drug’s full effect to be achieved, consistent daily use for up to two weeks may be observed, which is consistent with the medicine's documented mechanism of action.


Q: What happens if I forget to use Eltair one day?

If a scheduled use is missed, the instruction provided in official documents is to simply continue with the next scheduled use at the usual time. Official guidance indicates that users should not double the next dose or use more than prescribed to compensate for a missed use.


Q: Is Eltair approved for use in children or teenagers?

According to regulatory labels, Eltair is permitted for use in adults and children who are 6 years of age and older. Safety and effectiveness have not been established for children younger than 6 years of age.


Q: Can Eltair cause changes in mood or personality?

Official safety documentation, consistent with the corticosteroid class of medicines, includes reports of psychiatric disorders as potential adverse reactions. These documented reactions may include effects such as changes in mood, depression, or psychomotor hyperactivity.


Q: Does Eltair affect other conditions I might have, like high blood pressure?

Eltair is designed for localized delivery, so its systemic effects are expected to be low. However, because the active component is a corticosteroid, close monitoring may be required for patients who have certain pre-existing systemic conditions. It is generally advised that individuals inform their health care provider of all pre-existing medical conditions.


Q: What is the likelihood of experiencing a rare side effect with Eltair?

Regulatory agencies classify side effects based on how often they occur in clinical trials. A rare side effect is defined as one that is reported in between 1 in 1,000 and 1 in 10,000 patients who use the medicine.


Q: Has Eltair been studied in diverse patient populations?

Research documents note limitations regarding the diversity of patient populations studied in the primary trials. Limited information is available on outcomes for older adults (age 65 and older) and for pregnant or breastfeeding individuals, as these groups were generally excluded from primary efficacy trials.


Q: Is it true that the effectiveness of Eltair can vary from person to person?

Studies indicate that individual responses to the medicine can vary. Research documents report findings that describe general group patterns across many patients, rather than predicting the exact outcome or personal response for any individual person.


Q: Is Eltair the same kind of drug as [Similar Drug Name]?

Eltair's active ingredient, Budesonide, is classified pharmacologically as a corticosteroid (specifically a glucocorticoid). This pharmacological classification defines the way the medicine works, distinguishing it from other drug classes used to treat similar conditions.


Q: Are there any common foods or drinks that interact with Eltair?

Regulatory warnings specifically advise caution regarding the consumption of large amounts of grapefruit or grapefruit juice. This is because grapefruit can interfere with the way the body processes the medicine, which may increase the systemic exposure of the active ingredient.


Q: What should I do if a side effect of Eltair seems serious?

Official guidance recommends seeking immediate medical attention if a serious side effect is suspected. This is critical for reactions like severe, life-threatening allergic symptoms, such as swelling of the face, tongue, or difficulty breathing, which require urgent care.


Q: How long can a person continue to use Eltair?

Patients are advised to consult with a healthcare professional before using the medicine for longer periods. Using the medicine for a prolonged time, typically beyond a few months, may increase the risk of certain side effects.


Q: Are there any activities I should avoid while using Eltair?

Due to the potential for adverse reactions like dizziness or visual disturbances, it is advised to exercise caution until the medicine’s specific effects on an individual are known. This caution is generally applied when performing activities that require full mental alertness, such as driving.


Q: Is it true that Eltair is a new type of medication?

Eltair contains the established active ingredient Budesonide, which is a recognized corticosteroid. A nasal spray product containing Budesonide first received regulatory approval from the FDA in 1999.


Q: What is the difference between how Eltair works and how other drugs work?

The mechanism of Eltair involves its active ingredient binding to a receptor inside the cell, which then goes on to influence gene activity. This 'genomic modulation' acts to suppress inflammatory chemical signals while increasing the production of anti-inflammatory factors.


Q: Does Eltair interact with common over-the-counter pain relievers?

Regulatory documents do not specifically identify common non-prescription pain relievers as having a significant known interaction that requires avoidance. The most notable interaction warnings involve prescription medicines that affect the CYP3A4 enzyme system (a major metabolic pathway in the body).


Q: If I have kidney or liver issues, can I still use Eltair?

Regulatory labels state that patients with severe liver impairment should be monitored closely by a healthcare professional, as their systemic exposure to the medicine may be increased. No specific precaution or restriction is noted in regulatory labels regarding kidney function.


Q: Can using Eltair make you feel tired or dizzy?

Regulatory documents include reports of reactions such as dizziness or drowsiness as potential adverse reactions associated with the medicine.


Q: Does Eltair contain lactose or gluten?

The nasal spray formulation of Eltair is generally described in its excipient list as being free of common food allergens and fillers, including both lactose and gluten.


Q: Can Eltair affect my ability to drive or operate machinery?

Due to the potential for side effects like dizziness or visual disturbances, official guidance advises that patients exercise caution when driving or operating machinery until the effects of the medicine on them are known.


Q: What is the benefit of Eltair compared to no treatment at all?

Research evidence has documented the medicine's ability to help manage and control symptoms when compared to an inactive placebo (no treatment) in clinical trials.


Q: Can Eltair interact with herbal supplements like St. John's Wort?

The medicine is known to interact with strong inducers of the CYP3A4 enzyme system. Herbal supplements classified as strong inducers, such as St. John's Wort, are expected to reduce the systemic concentration of the active ingredient.


Q: How does Eltair affect the condition it is approved to treat?

The medicine affects the condition by suppressing key inflammatory chemical signals, such as cytokines and prostaglandins, directly at the site of application. This mechanism helps with the long-term control and prevention of chronic swelling and irritation.


Q: Are there any patient-reported warning signs for liver problems while on Eltair?

Although regular blood testing is mandated for monitoring, official guidance often suggests seeking medical attention if certain patient-reported signs of liver issues are experienced. These signs may include severe, unexplained nausea and vomiting, unusual weakness, or yellowing of the skin or eyes (jaundice).


Q: Why is Eltair contraindicated for people with certain heart conditions?

The regulatory documents for this single-product formulation of Budesonide nasal spray do not list a contraindication specifically related to heart conditions. The primary absolute contraindication specified in regulatory documents is known hypersensitivity to the active substance or excipients.


Q: Can Eltair be used with certain vitamins or minerals?

Official guidance advises patients to inform their healthcare provider about all medicines, including vitamins and mineral supplements. This allows the provider to consider if there are any known interactions or if close observation is appropriate.


Q: What types of research have been done on Eltair?

Research on Eltair has primarily involved placebo-controlled randomized clinical trials (RCTs). These studies were used to evaluate the drug's effects on symptoms of allergic rhinitis and objective measures, such as nasal polyp size.

How should Eltair be stored and disposed of?

How to Store and Dispose of Eltair?

Eltair (budesonide nasal spray) must be stored according to official regulatory specifications to maintain its stability.

Storage Conditions

Requirement Instruction
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Protect the bottle from light, excessive heat, and moisture.
Container Keep the container tightly closed and store in an upright position.
Child Safety The medicine must be kept out of the reach of children.

Disposal and Stability

The product must be discarded after the labeled number of sprays have been used or within the specified post-opening period (e.g., three months), even if some liquid remains. Unused or expired medication must be disposed of in accordance with local requirements, often by following instructions from a pharmacist or local pharmaceutical take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eltair found in:

A-Z Index: